pre-IPO PHARMA

COMPANY OVERVIEW

Navrogen, Inc. is a biotechnology company focused on the discovery of tumor produced HIO-factors that are associated with cancer prognosis and therapeutic response of immune-mediated anti-cancer therapies. Our mission is to develop diagnostic tests that can identify patients whose tumors produce HIO-factors to advise physicians on therapeutic options as well as develop first-in-class agents that can overcome the immuno-suppressive effects of a specific HIO-factor by employing our proprietary technologies.


LOCATION

  • Cheyney, PA, USA

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    http://navrogen.com


    CAREER WEBSITE


    SOCIAL MEDIA


    INVESTORS

    ben-franklin-technology-partners


    PRESS RELEASES


    Nov 7, 2022

    Navrogen Enters into CRADA with The U.S. National Cancer Institute for the Clinical Development of NAV-001, an Anti-Mesothelin Antibody-Drug Conjugate


    Mar 28, 2022

    Navrogen Presents Preclinical Data on Its NAV-001 Antibody-Drug Conjugate Program at the 12th World ADC Conference in London


    Nov 30, 2021

    Navrogen Announces Publication of Its Block-Removed Immunoglobulin Technology (BRITE) to Optimize Rituximab Activity in Humoral Immunosuppressed Cancers


    Sep 13, 2021

    Navrogen Enters Into CRADA With USAMRIID To Test Proprietary Small Molecule NK Cell Activators Against SARS-COV-2 Infection


    Aug 17, 2021

    Navrogen Inc. and Tavotek Biotherapeutics Announce Strategic Collaboration to Improve Therapeutic Efficacy of Antibody Pipeline Agents


    For More Press Releases


    Google Analytics Alternative